AI-Augmented Precision Oncology Pipeline

Title

AI-Augmented Precision Oncology Pipeline

Content

ConcertAI, a leading oncology real-world data and AI technology company, announced a multi-year strategic agreement with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the development and deployment of clinical AI algorithms and integrated imaging workflows for oncology clinical trials and clinical decision augmentation. MSK leverages ConcertAI's Eureka Life Science AI Platform, powered by TeraRecon, to build, test, and deploy AI-driven tumor detection, segmentation, and classification models for predicting tumor mutations and assessing cancer treatment response. The collaboration utilizes clinical and radiological imaging data from ConcertAI's network and publicly available data sources. By combining MSK's deep AI and radiology expertise with ConcertAI's multi-modal data capabilities, the organizations co-evolve common architectures and robust workflows to materially improve how medical images are processed, analyzed, and interpreted in clinical trials and clinical care. The goal is to enhance the speed, precision, and generalizability of AI models so more patients, trials, and institutions can benefit from clinical AI in precision oncology.

URL